Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

ABSTRACT: Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. This therapy relies on efficient replication of virus in tumor cells in vivo with minimal or no replication in normal tissues. We recently described GLV-1h68 as a modified Vaccinia Virus (VACV) construct with exclusive in vivo tropism for tumor cells in experimental animal models. Moreover, we had previously observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro during the first 20 hours following infection and the in vivo ability to colonize and eliminate the corresponding tumor implant. Thus, we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines, extensively characterized and used for the assessment of nove

ORGANISM(S): Homo sapiens

SUBMITTER: Ascierto ML 

PROVIDER: S-ECPF-GEOD-28472 | biostudies-other | 2011

REPOSITORIES: biostudies-other